Biovica, Uppsala, Sweden, has acquired cSens AB, Uppsala, Sweden, a company that has developed a polymerase chain reaction-based system for the analysis of serum thymidine kinase (TK) enzyme activity.

According to the companies, cSens’ caVet-TK1 technology complements Biovica’s TK assay, DiviTum, a highly sensitive assay for measuring cell proliferation. The caVet-TK1 assay enables monitoring of compounds regulating cell proliferation and the cell cycle. DiviTum is a tool for evaluating the efficacy of therapy in patients with advanced estrogen-receptor-positive breast cancer whose tumors have been treated with endocrine therapies and cyclin-dependent kinase-inhibitors.

In addition to providing the ability to measure TK clinically, cSens’ diagnostic system creates opportunities to expand preclinical measurements in cancer cell cultures and animal models. The system can also be used to develop new biomarker assays and tests for other forms of cancer and novel drugs.

Leif Glantz, cSens.

Leif Glantz, cSens.

“We look forward to become a part of Biovica and to access the network of world-leading oncologists and global pharmaceutical companies that Biovica works with,” says Leif Glantz, chairman of the board and CEO of cSens. “This creates a great opportunity for us to commercialize our technology, and it will be exciting to follow the development henceforth.”

“The technology complements Biovica well and creates new opportunities for us to provide a faster and more automated platform,” says Anders Rylander, CEO of Biovica. “Furthermore, we create new opportunities to face new diagnostic needs with the platform, and with the expertise of the cSens staff.”

For more information, visit Biovica.